Experimental RNA vaccine takes on advanced lung cancer

NCT ID NCT07561723

Recruiting now ⭐️ VACCINE ⭐️ Sponsor: West China Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing a new RNA vaccine called IMP3-saRNA (YMN-136) in 9 people with advanced non-small cell lung cancer who have run out of standard options. The vaccine aims to train the immune system to attack cancer cells that carry a specific marker (IMP3). The main goal is to check safety, but researchers will also look for signs that the vaccine shrinks tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IMP3-saRNA (YMN-136) vaccine
What this could lead to: If it works, this could point toward a new treatment option for advanced lung cancer that uses the immune system to fight tumors.
What could go wrong: This is a very early, small trial with only 9 people, so it may not show clear benefit. The vaccine could cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

West China Hospital, Sichuan University, Chengdu, Sichuan
RECRUITING

Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.